In the following video, Motley Fool health-care analyst David Williamson takes a look at NPS Pharmaceuticals' (UNKNOWN:NPSP.DL) very bold move. This small company has just bought back the worldwide rights to both of its lead drugs, Gattex and Natpara, from the giant corporation Takeda. David tells investors how challenging it will be for the NPS Pharmaceuticals to take over management of worldwide sales of the two drugs, as well as just how big the potential rewards from this move could be.

David Williamson has no position in any stocks mentioned. The Motley Fool recommends BioMarin Pharmaceutical. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.